Kynam Capital Management, LP Gossamer Bio, Inc. Transaction History

Kynam Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.78 - $1.82 $195,000 - $455,000	250,000 New	250,000 $207,000
Q1 2023 May 15, 2023	SELL	$0.96 - $2.92 $257,931 - $784,542	-268,679 Reduced 15.17%	1,502,866 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$1.74 - $12.87 $2.41 Million - $17.8 Million	1,385,196 Added 358.53%	1,771,545 $3.84 Million
Q3 2022 Nov 14, 2022	SELL	$7.21 - $14.88 $14.2 Million - $29.2 Million	-1,964,099 Reduced 83.56%	386,349 $4.63 Million
Q2 2022 Aug 15, 2022	BUY	$5.97 - $9.97 $3.09 Million - $5.16 Million	517,744 Added 28.25%	2,350,448 $19.7 Million
Q1 2022 May 13, 2022	BUY	$8.44 - $12.49 $6.89 Million - $10.2 Million	815,847 Added 80.23%	1,832,704 $15.9 Million
Q4 2021 Feb 14, 2022	BUY	$10.12 - $14.07 $10.3 Million - $14.3 Million	1,016,857 New	1,016,857 $11.5 Million

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $78.9M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.